Printer Friendly

IDEC PHARMACEUTICALS COMPLETES EXPANSION TO NEW HEADQUARTERS; UNIFIES ALL COMPANY OPERATIONS IN SAN DIEGO

 SAN DIEGO, June 28 /PRNewswire/ -- Today, IDEC Pharmaceuticals Corporation (NASDAQ: IDPH) has completed the unification of its Mountain View and La Jolla, Calif., staffs in a new corporate headquarters in San Diego. Through a team effort of IDEC employees, architects, developers, craftsmen from a variety of trades, and the City of San Diego, the company converted a building used in the defense industry into a state- of-the-art, 73,000-square-foot pharmaceutical facility. The building, which houses the current IDEC staff of 128 employees in administrative, R&D, medical, regulatory, process development, quality control and manufacturing operations, also provides room for corporate growth as products near commercialization. "We are particularly pleased that so many of our Mountain View group have been able to join our new team in San Diego," said William H. Rastetter, Ph.D., company president and chief executive officer.
 Within the IDEC facility, the clinical manufacturing plant is still under construction and should be completed this fall. Although this unit occupies only 20 percent of the new headquarters building, it will have the capacity to meet clinical and early commercialization needs. This high efficiency is possible via an exceptional, molecular-biology- based, cell-culture system that is substantially more productive than those generally reported by other antibody manufacturers. "This system should translate into a lower cost of goods and the ability to meet our future needs for products -- for clinical trials and ultimately for commercialization -- from this modest-sized plant," added Rastetter. The pilot plant is being constructed and validated to standards that will support Product License Applications (PLA) and Establishment License Applications (ELA) to the U.S. Food and Drug Administration.
 "We achieved the entire process -- from site selection, through build-out, to occupancy -- in just over one year," stated Rastetter. The interior layout of the empty shell at 11011 Torreyana Road was designed by architects at McGraw/Baldwin of San Diego. The Del Mar Partnership, Del Mar, developed the project on behalf of the building owner, Torrey Sorrento Inc., La Jolla, and was responsible for creative financing. The landlord's portion of the extensive build-out was financed by Seidler Realty Advisors, San Diego, as part of the 15-year lease. Rudolph and Sletten Inc., Foster City, was the general contractor.
 IDEC Pharmaceuticals is focused on the development of targeted immunotherapies for the treatment of cancer and autoimmune diseases. Within this strategic focus, the company's most advanced product candidates are directed at the treatment of B-cell lymphomas, malignant melanoma and rheumatoid arthritis. These agents typically are designed to act through immune system mechanisms and potentially offer greater specificity of action, longer therapeutic effect and lower toxicity than is typical of existing therapies. They also can be administered in outpatient settings, potentially helping to reduce overall treatment costs.
 IDEC Pharmaceuticals is proud to now be unified at 11011 Torreyana Road, San Diego, CA 92121. Please note the company's new numbers: phone: 619-550-8500, fax: 619-550-8750.
 -0- 6/28/93
 /CONTACT: Richard Krawiec, director of investor relations and corporate communications, or William H. Rastetter, president and CEO, of IDEC Pharmaceuticals, 619-550-8656/
 (IDPH)


CO: IDEC Pharmaceuticals Corp. ST: California IN: MTC SU:

MF-JL -- SD002 -- 6109 06/28/93 09:04 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 28, 1993
Words:523
Previous Article:TRANS PACIFIC GROUP INC. ACQUIRES NATIONAL DATA-SEARCH INC.
Next Article:FIRST UNION COMPLETES LARGEST SYSTEMS CONVERSION IN U.S. BANKING HISTORY
Topics:


Related Articles
IDEC PHARMACEUTICALS SIGNS LEASE FOR UNIFIED CORPORATE HEADQUARTERS AND PILOT PLANT
WILLIAM ROHN JOINS IDEC PHARMACEUTICALS AS SENIOR VICE PRESIDENT, COMMERCIAL AND CORPORATE DEVELOPMENT
DAVID LUDVIGSON JOINS IDEC PHARMACEUTICALS AS SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER
IDEC PHARMACEUTICALS REPORTS THIRD QUARTER 1993 RESULTS
IDEC PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR-END 1993 RESULTS
IDEC PHARMACEUTICALS AND GENENTECH EXPAND COLLABORATION ON LYMPHOMA DRUG TO JAPAN AND ASIA
JOHN GEIGERT JOINS IDEC PHARMACEUTICALS AS VICE PRESIDENT, QUALITY
IDEC PHARMACEUTICALS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters